Shares in drug developer Hutchmed (China) (LON:HCM) soared on news the firm had signed a licence deal with GSK (LON:GSK). The licence gives GSK worldwide rights, excluding China, Hong Kong and Taiwan, to develop and market one of Hutchmed’s cancer therapies. Licence deal with GSK Hutchmed has signed over the commercial rights to its KRAS-EGFR … Continue reading Hutchmed (China) soars on GSK licence deal